Low-frequency Repetitive Transcranial Magnetic Stimulation for Treatment of Tourette Syndrome: A Naturalistic Study with 3 Months of Follow-up

Swarndeep Singh, Saurabh Kumar, Nand Kumar, Rohit Verma

ABSTRACT

The objective of this study is to report the effects of low-frequency repetitive transcranial magnetic stimulation (rTMS) in three patients with medication-refractory Tourette syndrome (TS) and over 3-month follow-up. A review of literature on the use of rTMS for the treatment of TS is also presented. Three patients with severe, medication-refractory TS and comorbid obsessive-compulsive disorder (OCD) in two of them, received an open-label trial of rTMS at 1 Hz frequency for 4-week duration. The first two cases of TS-OCD showed, on average, around 57% improvement in Yale Global Tic Severity Scale (YGTSS) scores (65% and 50%) and 45% improvement in Yale-Brown Obsessive-compulsive Scale (Y-BOCS) scores; however, the third case of pure-TS showed marginal improvement of 10% only. The improvement in TS-OCD patients with rTMS treatment was maintained at the end of 3-month follow-up, with an average reduction of about 49% (58% and 40%) and 36% observed in YGTSS and Y-BOCS scores, respectively. The present study supports the use of low-frequency rTMS to improve tics and OCD symptoms in patients with severe, medication-refractory TS-OCD. Further, the beneficial effects of rTMS treatment were maintained substantially over 3-month follow-up period.

Key words: Obsessive-compulsive disorder, repetitive transcranial magnetic stimulation, Tourette syndrome

INTRODUCTION

Tourette syndrome (TS) is a complex neuropsychiatric disorder and characterized by multiple motor and phonic tics. The majority of patients with TS experience complete or near-complete remission of tics, but in about 10%–20% of TS cases, tics persists or worsens during adulthood. Motor and/or vocal tics are perceived by both the patients with TS and their family members as one of the most significant and bothersome symptoms of TS and that should be treated. Management strategies commonly used for TS include reassurance, psychoeducation, cognitive behavioral therapy involving habit reversal training and exposure-response prevention, and pharmacotherapy with two main classes

How to cite this article: Singh S, Kumar S, Kumar N, Verma R. Low-frequency repetitive transcranial magnetic stimulation for treatment of tourette syndrome: a naturalistic study with 3 months of follow-up. Indian J Psychol Med 2018;40:482-6.
of drugs such as alpha-2 adrenergic agonists (guanfacine and clonidine) and antipsychotics (typical and atypical). However, approximately, one-third of patients with TS do not benefit from the abovementioned treatment strategies, and many of the medications used to treat tics produce significant side effects.[3]

Therefore, novel, noninvasive, and safer treatment strategies such as repetitive transcranial magnetic stimulation (rTMS) need to be explored to reduce tics, especially in patients with severe, refractory TS. This is a noninvasive brain stimulation technique which uses repetitive brief, intense magnetic fields generated by a coil placed over the scalp producing an electric field in the underlying brain region through electromagnetic induction. In general, high-frequency (>5 Hz) rTMS promotes cortical excitability and low-frequency (1 Hz) rTMS inhibits cortical excitability.[4] Here, we report the effect of low-frequency rTMS (1 Hz) over bilateral supplementary motor area (SMA) in three patients with TS. A review of the literature on the use of rTMS for the treatment of TS is presented. The durability of the effects of rTMS in TS patients over 3-month follow-up is also reported.

METHODS

Three patients with severe, medication-refractory TS, and comorbid obsessive-compulsive disorder (OCD) in two of them (according to the International Classification of Diseases-10), presenting to the psychiatry outpatient clinic and given an open-label trial of low-frequency rTMS in accordance with the updated safety guidelines,[3] are described in this naturalistic study. Magstim Rapid TMS device (Whitland, UK) with a 70-mm figure-of-eight air film coil was used to administer rTMS. The resting motor evoked potential (MEP) was determined in accordance with the International Federation of Clinical Neurophysiology recommendations.[3] The resting motor threshold (RMT) was defined as the minimum stimulus intensity that produced an MEP in five out of 10 trials at rest. The stimulation parameters used were 1-Hz frequency, stimulation intensity at 110% of RMT, about 30 min sessions once/day (900 pulses/day), and 5 days/week (from Monday to Friday) for a total of 4 weeks (total of 20 sessions). The medications of all three patients were kept same for at least 12 weeks before and during the study period. The vertex was measured for each patient using the International 10–20 EEG System coordinates, and SMA was defined as 15% of the distance between inion and nasion anterior to the vertex on the sagittal midline. The coil was placed with the handle along the sagittal midline and pointing toward occiput to stimulate bilateral SMA simultaneously.

RESULTS

Case 1

A 24-year-old male with TS since 14 years of age and comorbid OCD for the past 4 years, presented with baseline Yale Global Tic Severity Scale (YGTSS) and Yale-Brown Obsessive Compulsive Scale (Y-BOCS) scores of 62/100 and 28/40, respectively. In treatment history, he had failed to respond to adequate dosages and durations of pharmacotherapy trials with typical and atypical antipsychotics (haloperidol up to 4 mg/day and risperidone up to 4 mg/day), selective serotonin reuptake inhibitors (fluoxetine up to 60 mg/day and clomipramine up to 300 mg/day), and tetrabenazine (150 mg/day). He was currently taking pimozide (6 mg/day), trihexyphenidyl (2 mg/day), fluoxetine (60 mg/day), and clonazepam (3 mg/day). The secondary causes of tics and OCD were ruled out. After obtaining informed written consent from the patient, he was given low-frequency rTMS following the study protocol. The patient reported decrease in tics and improvement in OC symptoms after a week of starting rTMS, with reduction in YGTSS and Y-BOCS scores to 22/100 and 14/40, respectively, at the end of 20 rTMS sessions. The changes in YGTSS and Y-BOCS score at 3-month follow-up period are described in Table 1.

Case 2

A 18-year-old male with TS since 8 years of age and comorbid OCD for the past 2 years, presented with baseline YGTSS and Y-BOCS scores of 86/100 and 26/40, respectively. In treatment history, he had failed to respond to adequate dosages and durations of pharmacotherapy trials with typical and atypical antipsychotics (pimozide up to 8 mg/day and risperidone up to 4 mg/day) and selective serotonin reuptake inhibitors (fluoxetine up to 60 mg/day and clomipramine up to 300 mg/day). He was currently taking fluphenazine (10 mg/day), trihexyphenidyl (2 mg/day), sertraline (200 mg/day), and clonazepam (6 mg/day). The secondary causes of tics and OCD were ruled out. After obtaining informed written consent from the patient, he was given low-frequency rTMS following the study protocol. The patient reported decrease in tics and improvement in OC symptoms after a week of starting rTMS, with reduction in YGTSS and Y-BOCS scores to 43/100 and 16/40, respectively, at the end of 20 rTMS sessions. The changes in YGTSS and Y-BOCS score at 3-month follow-up period are described in Table 1.

Case 3

A 15-year-old female with TS since 11 years of age and no comorbid psychiatric disorder, presented with baseline YGTSS score of 60/100. There was a
family history of tic disorder in her father and sister. In treatment history, she had failed to respond to adequate dosages and durations of pharmacotherapy trials with haloperidol (up to 4 mg/day), risperidone (up to 4 mg/day), and clonidine (up to 0.3 mg/day). At the time of presentation, she was taking pimozide (6 mg/day) and trihexyphenidyl (2 mg/day). Secondary causes of tic disorders were ruled out. After taking informed written consent from parent and assent from the patient, she was given low-frequency rTMS following the study protocol. There was no clinically significant improvement in her symptoms, with YGTSS score showing slight reduction to 54/100 at the end of 20 rTMS sessions over 4 weeks.

**DISCUSSION**

Although the exact pathogenesis of TS is not yet fully understood, emerging knowledge about neurocircuitry underlying TS can be used to guide and design focal brain stimulation techniques to treat TS. Recent neuroimaging studies have implicated overactivity of SMA to be responsible for tics and premonitory urges which seen in TS. In our electronic literature search employing PubMed and Google Scholar databases, we found a total of nine clinical studies on the use of low-frequency rTMS for the treatment of TS, with maximum evidence for stimulation of bilateral SMA as expected. However, most of these human studies were of either open-label design or single-blind randomized crossover design, with no follow-up study periods assessing the durability of the effects of rTMS. A single double-blind, randomized, placebo-controlled trial was identified in our review, which showed no statistically significant difference between active and sham rTMS in reduction of tics. This could be due to small number of patients (n = 20) or differences in stimulation parameters used in the study (3 vs. 4 weeks in the present study).

The first two cases of TS-OCD showed an average improvement of around 57% in YGTSS scores (65% and 50%) and 43% in Y-BOCS scores, that matches or exceeds the percent improvement seen with currently approved behavioral or pharmacological interventions for TS. In contrast, the third case of pure-TS showed minimal improvement of 10% only. This could be due to the inherent differences between TS syndromes according to associated comorbidities, with recent neuroimaging studies supporting the role of unique networks in the TS-OCD syndrome as opposed to pure-TS. This differential response with rTMS treatment may be explained by the involvement of different neural networks in TS as opposed to TS-OCD syndrome. Similar findings have been reported in few previous studies of rTMS for the treatment of TS, with significant reduction of tics seen for TS-OCD but not for all TS patients. The third case was of a younger girl and with a positive family history for tics disorder which might have contributed to the differential treatment response with rTMS, observed in the present study.

The rTMS sessions were safe and well tolerated with no significant side effects reported by none of the three patients. The beneficial effects of rTMS treatment in TS-OCD patients were maintained substantially at the end of 3-month follow-up, with an average reduction of about 49% (58% and 40%) and 36% (42% and 30%) observed in YGTSS and Y-BOCS scores, respectively.

**CONCLUSIONS**

The present study supports the use of low-frequency rTMS (1-Hz) over bilateral SMA as an adjunctive treatment to improve tics and OCD symptoms in severe, medication-refractory TS-OCD syndrome. The lack of treatment effect seen in pure-TS patient may assist in the identification of the TS population responsive to inhibition of the SMA in the future studies. The beneficial effects of rTMS treatment were maintained substantially over the 3-month follow-up period. In future, larger, double-blind, randomized placebo-controlled studies with higher number (total number of rTMS sessions and pulses delivered) of rTMS stimulation treatments and long-term follow-up periods should be done to confirm the findings of the present study and to determine the sustainability of the effects of rTMS and to explore the need of maintenance rTMS protocols for continuing the beneficial effects of rTMS treatment.

**Financial support and sponsorship**

Nil.
Table 2: Review of clinical studies on use of repetitive transcranial magnetic stimulation for the treatment of Tourette syndrome

| First author and year | Study design | Study population | Stimulation parameters (frequency, intensity, and number of pulses/day) | Target brain area | Result |
|-----------------------|--------------|------------------|-------------------------------------------------|------------------|--------|
| Münchau, 2002[9]      | Single-blind, placebo-controlled, crossover study | n=16 TS (7°CD) 12 males; 38±12.3 years | 1-Hz, 80% of RMT, and 1200 pulses/day | Left MC or left PMC | No significant improvement with any of the rTMS conditions |
| Chae, 2004[10]        | Single-blind, placebo-controlled, crossover study | n=8 TS (4°CD) 5 males; 14.9±16 years | 1-Hz, 110% of RMT, and 2400 pulses/day | Left MC or left PFC | Improvement in tics and OCD with time, irrespective of site, or frequency of rTMS |
| Orth, 2005[11]        | Single-blind, placebo-controlled, crossover study | n=5 TS (0°CD) 4 males; age range: 19-52 years | 1-Hz, 80% of RMT, and 1800 pulses/day | Left PMC f/b right PMC | No significant improvement with any of the rTMS conditions |
| Mantovani, 2006[12]   | Open-label study | n=10 (5°CD, 3 TS, 2 TS + OCD) 8 males; 33.5±13.5 years | 1-Hz, 100% of RMT, and 1200 pulses/day | Bilateral SMA | Significant improvement in tics and OCD symptoms |
| Mantovani, 2007[13]   | Open-label study | n=2 TS + OCD; 16 and 22 years | 1-Hz, 110% of RMT, and 1200 pulses/day | Bilateral SMA | Significant improvement in symptoms of TS and OCD |
| Kwon, 2011[14]        | Open-label study | n=10 TS (1°CD) 10 males; 11.2±2.0 years | 1-Hz, 100% of RMT, and 1200 pulses/day | Bilateral SMA | Significant improvement in tics and comorbid conditions |
| Le, 2013[15]          | Open-label study | n=25 TS (0°CD) 22 males; 10.6±2.2 years | 1-Hz, 110% of RMT, and 1200 pulses/day | Bilateral SMA | Significant improvement in tics and OCD |
| Bloch, 2016[16]       | Open-label study | n=12 TS (6°CD) 6 males; 32.6±12.7 years | 1-Hz, 110% of RMT, and 1200 pulses/day | Bilateral SMA | No significant improvement in tics among the group as a whole; subgroup analysis of six patients with TS + OCD showed significant improvement in tic severity |
| Landeros-Weisenberger, 2015[17] | Phase 1: Randomized double-blind, sham-controlled trial for 3 weeks | n=20 TS (5°CD) 16 males; 33.7±12.2 years | 1-Hz, 110% of RMT, and 1200 pulses/day | Bilateral SMA | Phase 1: No statistically significant difference in reduction of tic severity between active and sham rTMS |
|                       | Phase 2: Additional open-label active treatment of Phase 1 randomized active rTMS arm for another 3 weeks | n=7 | | | Phase 2: Statistically significant reduction of 29.7% in tic severity compared to baseline |

n – Sample size; OCD – Obsessive-compulsive disorder; RMT – Resting motor threshold; MC – Motor cortex; PMC – Premotor cortex; PFC – Prefrontal cortex; SMA – Supplementary motor area; rTMS – Repetitive transcranial magnetic stimulation; TS – Tourette syndrome; f/b – Followed by

Conflicts of interest
There are no conflicts of interest.

REFERENCES

1. Bloch MH, Peterson BS, Scahill L, Otkar J, Katsovich L, Zhang H, et al. Adulthood outcome of tic and obsessive-compulsive symptom severity in children with Tourette syndrome. Arch Pediatr Adolesc Med 2006;160:65-9.
2. Ghanizadeh A, Mohammadi MR, Dehbozorgi GR. Children and their parent’s perceptions of symptom severity and treatment preference for Tourette syndrome. Iran J Psychiatry 2010;5:33-6.
3. Martino D, Leckman J, editors. Tourette Syndrome. New York: Oxford University Press; 2013.
4. Di Lazzaro V, Dileone M, Pilato F, Capone F, Musumeci G, Ranieri F, et al. Modulation of motor cortex neuronal networks by rTMS: Comparison of local and remote effects of six different protocols of stimulation. J Neurophysiol 2011;105:2150-6.
5. Rossi S, Hallett M, Rossini P, Pascual-Leone A. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol 2009;120:2008-39.
6. Eichele H, Plessen KJ. Neural plasticity in functional and anatomical MRI studies of children with Tourette syndrome. Behav Neurol 2013;27:33-45.
7. Neuner J, Schneider F, Shah NJ. Functional neuroanatomy of the rTMS conditions. Int Rev Neurobiol 2013;112:35-71.
8. Münchau A, Bloem BR, Thilo KV, Trimble MR, Rothwell JC, Robertson MM, et al. Repetitive transcranial magnetic stimulation for Tourette syndrome. Neurology 2002;59:1789-91.
9. Chae JH, Nahas Z, Wassermann E, Li X, Sethuraman G, et al.: Effect of low-frequency rTMS in tourette syndrome.
Gilbert D, et al. A pilot safety study of repetitive transcranial magnetic stimulation (rTMS) in Tourette’s syndrome. Cogn Behav Neurol 2004;17:109-17.

10. Orth M, Kirby R, Richardson MP, Snijders AH, Rothwell JC, Trimble MR, et al. Subthreshold rTMS over pre-motor cortex has no effect on tics in patients with gilles de la Tourette syndrome. Clin Neurophysiol 2006;116:764-8.

11. Mantovani A, Lisanby SH, Pieraccini F, Ulivelli M, Castrogiovanni P, Rossi S, et al. Repetitive transcranial magnetic stimulation (rTMS) in the treatment of obsessive-compulsive disorder (OCD) and Tourette’s syndrome (TS). Int J Neuropsychopharmacol 2006;9:95-100.

12. Mantovani A, Leckman JF, Grantz H, King RA, Sporn AL, Lisanby SH, et al. Repetitive transcranial magnetic stimulation of the supplementary motor area in the treatment of Tourette syndrome: Report of two cases. Clin Neurophysiol 2007;118:2314-5.

13. Kwon HJ, Lim WS, Lim MH, Lee SJ, Hyun JK, Chae JH, et al. 1-hz low frequency repetitive transcranial magnetic stimulation in children with Tourette’s syndrome. Neurosci Lett 2011;492:1-4.

14. Le K, Liu L, Sun M, Hu L, Xiao N. Transcranial magnetic stimulation at 1Hertz improves clinical symptoms in children with Tourette syndrome for at least 6 months. J Clin Neurosci 2013;20:257-62.

15. Bloch Y, Arad S, Levkovitz Y. Deep TMS add-on treatment for intractable Tourette syndrome: A feasibility study. World J Biol Psychiatry 2016;17:557-61.

16. Landeros-Weisenberger A, Mantovani A, Motlagh MG, de Alvarenga PG, Katsoyich L, Leckman JF, et al. Randomized sham controlled double-blind trial of repetitive transcranial magnetic stimulation for adults with severe Tourette syndrome. Brain Stimul 2015;8:574-81.

17. Scahill L, Erenberg G, Berlin CM Jr., Budman C, Coffey BJ, Jankovic J, et al. Contemporary assessment and pharmacotherapy of tourette syndrome. NeuroRx 2006;3:192-206.

18. Pourfar M, Feigin A, Tang CC, Carbon-Correll M, Bussa M, Budman C, et al. Abnormal metabolic brain networks in Tourette syndrome. Neurology 2011;76:944-52.

19. Ganos C, Roessner V, Münchau A. The functional anatomy of Gilles de la Tourette syndrome. Neurosci Biobehav Rev 2013;37:1050-62.